Mortality at maximal · people with primary biliary cholangitis
It is very uncertain whether azathioprine changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number of events) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · people with primary biliary cholangitis
It is very uncertain whether colchicine changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
All‐cause mortality · heart failure in patients with Chagas cardiomyopathy
It is very uncertain whether carvedilol changes all‐cause mortality compared with placebo (very low certainty).
1 finding from 1 review
Time to heart decompensation · chronic heart failure in Chagas cardiomyopathy patients
1 finding from 1 review
Disease‐free period at 30, 60 and 90 days · chronic heart failure in Chagas cardiomyopathy patients
1 finding from 1 review
Quality of life · chronic heart failure in Chagas cardiomyopathy patients
1 finding from 1 review
Adverse events · chronic heart failure in Chagas cardiomyopathy patients
1 finding from 1 review
Hospital readmissions (heart failure‐ or adverse event‐related) · chronic heart failure in Chagas cardiomyopathy patients
1 finding from 1 review
Cardiac mortality · heart failure in patients with Chagas cardiomyopathy
1 finding from 1 review
Time to heart decompensation · heart failure in patients with Chagas cardiomyopathy
1 finding from 1 review
Disease‐free period at 30, 60 and 90 days · heart failure in patients with Chagas cardiomyopathy
1 finding from 1 review
Overall survival · heart failure in patients with Chagas cardiomyopathy
1 finding from 1 review
Quality of life · heart failure in patients with Chagas cardiomyopathy
1 finding from 1 review
Adverse events · heart failure in patients with Chagas cardiomyopathy
It is very uncertain whether carvedilol changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
All‐cause mortality · chronic heart failure in Chagas cardiomyopathy patients
1 finding from 1 review
Cardiac mortality · chronic heart failure in Chagas cardiomyopathy patients
1 finding from 1 review
Incidence of pain with lidocaine pretreatment Pain scales · adults and children undergoing general anaesthesia including the muscle relaxant rocuronium bromide
Lidocaine may leads to lower pain ‐ lidocaine compared with placebo (low certainty).
1 finding from 1 review